/
BIO
$291.93-$3.37 (-1.14%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$8.0B
27M shares
52-week range
$236.73 – $343.12
52% from low
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Exchange
NYSE
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-365.78
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.29B | $2.31B | $2.55B | $2.92B | $2.80B | $2.67B | $2.57B | $2.58B |
| Cost of revenue | $1.07B | $1.05B | $1.11B | $1.28B | $1.23B | $1.24B | $1.19B | $1.24B |
| Gross profit | $1.22B | $1.26B | $1.44B | $1.64B | $1.57B | $1.43B | $1.38B | $1.34B |
| Gross margin | 53.5% | 54.4% | 56.5% | 56.1% | 55.9% | 53.4% | 53.7% | 52.0% |
| R&D | $199.2M | $202.7M | $217.8M | $260.6M | $256.9M | $247.4M | $295.9M | $256.9M |
| Operating income | −$108.6M | $229.7M | $421.3M | $500.3M | $482.6M | $337.8M | $269.0M | $270.5M |
| EBITDA | $674.7M | $2.46B | $5.08B | $5.59B | −$4.49B | −$654.8M | −$2.14B | $1.25B |
| Net income | $361.0M | $1.76B | $3.81B | $4.25B | −$3.63B | −$637.3M | −$1.84B | $759.9M |
| Net margin | 15.8% | 76.1% | 149.8% | 145.6% | -129.5% | -23.9% | -71.9% | 29.4% |
| EPS (diluted) | 11.94 | 58.27 | 126.20 | 140.83 | -121.79 | -21.82 | -65.36 | 27.87 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2.6B | $9.04 | $8.81–$9.22 | 2 |
| 2027 | $2.7B | $9.96 | $9.71–$10.16 | 2 |
| 2028 | $2.8B | $11.15 | $10.86–$11.36 | 1 |
| 2029 | $2.8B | $12.17 | $11.85–$12.41 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Bio-Rad Laboratories, Inc.Class A
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
www.bio-rad.com- Employees
- 7,450
- IPO / List date
- Feb 29, 1980
- HQ
- HERCULES, CA
Held by traders on TradeandTell
No one on the platform currently holds BIO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2026-03-31 | 1,684 | $469.4K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BIO yet.
